A “sky-high” vaccine that prevents 12 types of cancer is said to be making the rounds among the high-end population.
According to a tweet circulating online, the vaccine, called “DCV cancer vaccine” and issued by Hong Kong-based MDX Medical Group, can prevent more than 12 types of cancer for up to 98,000 yuan per shot, using technology from Japan that has been approved by Japan’s Health ministry.
Photos of Ms. Yang participating in the promotion appeared in the post.
“As a mother, I chose to vaccinate my daughter against HPV for cervical cancer,” She said, according to the marketing document.
Now DCV cancer vaccine launch, more exciting!
Is this a medical miracle, or are rich people “cutting leeks”?
Do celebrity endorsements really work?
Are products that chafe at biotech fever to be believed?
Does one shot prevent 12 kinds of cancer?
The above mentioned, DC vaccine dendritic main ingredients contained in the WT1, is approved by ministry of Japan, by Japanese MEDISUM cell laboratory co., LTD production of prophylactic broad-spectrum tumor vaccine (Borad spectrum tumor vaccine), to be effective in preventing more than 12 types of cancer, including colorectal cancer, kidney cancer, prostate cancer, ovarian cancer, lung cancer, breast cancer, gastric cancer, cervical cancer, lymphatic cancer, liver cancer, nasopharyngeal carcinoma, pancreatic cancer, esophageal cancer, etc.
Tens of thousands of patients have been injected to prevent and prevent recurrence.
It is understood that the full name of DCV Vaccine is Dentritic Cell Vaccine, where DC stands for dendritic Cell, which is an important immune Cell in all human bodies.
V is the Vaccine Vaccine.
So DCV, which translates to dendritic cell vaccine, doesn’t seem to have anything to do with cancer itself.
By improving the body’s ability to process antigens, such as immune activity, the vaccine induces CTL cells to recognize and kill cancer cells in the body, thereby avoiding the risk of recurrence of malignant tumours at the root of the disease, the extension claims.
However, according to a 21st Century Business Herald survey, the ministry of Health and Welfare’s guidelines on the scope of advanced medical care did not include the project.
The tweet included a screenshot of the Health, Labor and Welfare Ministry’s website from April 2018, but the page is no longer publicly available.
The ministry of Health, Labor and Welfare has updated the application scope of advanced medical treatment on its website with the latest update date of June 1, 2020.
It can be confirmed that the project is not included in the existing scope.
Cancer treatment options on the site include radiofrequency ablation of uterine adenomyosis, proton therapy, heavy ion beam therapy, drug resistance gene testing in anti-tumor drug therapy, but no description of DCV vaccine was found.
Current screenshot of the website of Japan’s Ministry of Health, Labour and Welfare
A director of cancer surgery at a third-level first-class hospital told the 21st Century Business Herald that the above-mentioned vaccine against 12 types of cancer is a hoax. There is no vaccine that can prevent many types of cancer in the world, and there is no preventive vaccine for many cancers at present.
Many industry experts told the 21st Century Business Herald that cancer can be early prevention, early detection, early treatment.
Pan Changqing, director of the Shanghai Chest Hospital, said tumors are caused by genetic mutations or changes, and the treatment is very complex.
Molecular biotechnology, especially gene detection, is an important technology in precision medicine. Through early screening of patients, it can turn passive into active and help improve the survival rate of patients, which has become an important direction of tumor therapy.
According to promotional materials, the main component of the DCV vaccine is WT1, which has been approved by Japan’s Ministry of Health and Welfare.
Meanwhile, as for the efficacy of WT1, the company’s promotional materials are described as follows:
The WT1 gene is a human tumorigenesis gene that is implicated in all human cancers.
The Nobel Institute for Biomedical Sciences has discovered a pathway that inhibits mutations in the WT1 gene, which, through vaccination, causes the body to produce memory T cells that inhibit mutations in the WT1 gene and are immune to the body.
Dr. Tawlina, the vaccine expert, said that in consultation with prominent oncologists in China, the WT1 gene is similar to the well-known p53 gene, which is expressed in many tumors but is not a promoter.
Now in addition to cervical cancer vaccine, other cancer vaccine in research, but there is no conclusion, more did not use in clinical.
According to one cancer expert, WT1 is a tumor suppressor that has been associated with some cancers.
But mutations in genes that cause cancers are mostly caused by mutations in oncogenes, and those that inhibit them are only a small fraction.
Therefore, from the perspective of probability, it is unlikely that WT1 will provide lifelong immunity to cancer as advertised, and even if the vaccine is useful, its immunity against cancer is very limited.
And no research has found any evidence that vaccines can prevent cancer by altering human genes, and their effectiveness is questionable.
A long-time industry insider who has been following advanced treatments in Japan told 21st Century Business Herald that WT1 is currently being studied in Japan, but the consistency between the findings and the company’s claims has yet to be verified.
No general clinical treatment has been reported, and studies at Osaka University are ongoing.
Hao Youcun, secretary to the chairman of Xi ‘an Shangshanfuyuan Health Management Consulting Co., which works closely with several Japanese medical institutions, told 21st Century Business News that in past cases, if the research was conducted in China and not approved by the state, the authenticity of the conclusions, such as stem cells against aging, was questionable.
The company’s so-called anti-cancer vaccine has not yet been approved by the National Health Commission, nor has it been included in the latest advanced medical treatment in The Province of Japan, which is likely to be problematic.
Many similar Hong Kong institutions by the craze of Hong Kong vaccine injection, illegal, illegal vaccine injection, the effectiveness and safety of its vaccine doubt.
The 21st Century Business Herald further found that the research institution mentioned in the promotion article is called “Nobel Academy of Ecological Medical Sciences”. After online search, only one institution called Nobel Hospital can be found, which is advertised as “China’s first Nobel Medical achievement transformation base”.
There is also a 7-minute video in the hospital, in which the young Dean Huang Li puts forward the concept of “ecological restoration system in the body” in English on the platform, which is not very good at English.
In addition, 21st Century Business Herald also found an enterprise named “Hainan Noble Institute of Ecological Medicine Science Co., LTD.”, whose business scope includes medical technology and equipment research, technology transfer and related product sales, etc.
It is understood that the company was founded in 2017 and contradicted more than 28 years of research promoted by twitter.
Fight aging with stem cells?
High-end crowd in the circle, in addition to the spread of cancer vaccine, but also often out of the rich to receive stem cell anti-aging treatment, rich 1.56 million to buy life anti-aging supplements……
Recently, some organizations have packaged stem cells as “do-everything cells” that can fight aging and cure everything.
But does injecting stem cells really work?
It is understood that stem cells, also known as “seed cells”, are a group of cells with the potential of self-renewal, high proliferation and multidirectional differentiation. In the medical field, depending on their “dryness”, they are expected to achieve cell replacement and tissue regeneration.
On September 26, 2018, the top international academic journals published online in nature, review articles, Japan RIKEN research institute (RIKEN) researcher and professor at keio university project Douglas Sipp, the United States national institutes of health (NIH), a senior researcher at Pamela G.R obey, associate professor, center for bioethics at the university of Minnesota Leigh Turner three warnings, stem cell concept confusion, makes the unproven therapies are easier to sell to patients.
In fact, in the 21st century, so-called “mesenchymal stem cell” research is rife with contradictions, including their origin, differentiation potential, biological function and potential therapeutic USES.
The phenomenon has prompted biologists, clinicians and scientific societies to recommend that the name be changed or abandoned.
“Scientists around the world need to work together to improve the biological understanding of the cells currently called MSCs, and researchers, journal editors and others need to commit to more precise naming.
We use standardized analyses of gene expression and rigorous tests to determine the precise products of cell differentiation in different tissues.”
Douglas et al. pointed out in their paper that only through “scientific solutions” can the problems surrounding the identity and function of MSCs be completely ended and the myth of MSCs be broken.
While MSCs has been dabbling in the stem cell field, companies have been peddling therapies that purportedly are based on MSCs.
There has been an explosion in the past five years in the US, Australia and Japan of consumer-directed but unapproved treatments for medical use.
A 2016 report documented 351 U.S. companies selling so-called stem cell therapies to consumers, and almost half mentioned MSCs in their marketing materials.
To convince consumers that MSCs can treat a wide range of diseases and injuries, companies have selectively highlighted papers that point out that MSCs are readily available and can produce other types of cells or secrete a wide variety of therapeutic factors.
In fact, a large number of studies have shown that, compared with totipotent stem cells such as embryonic stem cells, MSCs currently classified as adult stem cells have limited “dryability” and can only differentiate into a limited type of cell, which has been neglected in the so-called “stem cell therapy”.
History of mesenchymal stem cell naming and number of papers published annually since 1991
Although many basic studies have proved that this type of stem cell has strong differentiation ability and has the potential to be used in the treatment of many diseases, many problems remain to be solved.
First, autologous mesenchymal stem cells can survive ectopic in vivo for no more than two weeks.
Second, the differentiation of mesenchymal stem cells is still in the basic research stage, and uncontrolled differentiation is likely to induce inflammation, produce scar tissue, and even lead to cancer.
Third, between the self generally comes from fat, mesenchymal stem cells in the middle of the fat quantity of mesenchymal stem cells is not much, if in order to obtain a sufficient number of cells, often will increase the amount of liposuction or in vitro, the former is easy to increase the probability of liposuction patients died, the latter will increase the risk of uncontrolled, such as cell differentiation, cancer, etc.
In conclusion, autologous mesenchymal stem cell transplantation has not been clinically proven to be suitable for cosmetic purposes.
Some beauty agencies promote direct blood injection of stem cells is not desirable.
If the amount of stem cells injected is not strictly clinically verified, it is likely to cause capillary embolism when circulating in the blood, resulting in local necrosis.
If the embolism occurs in the lungs, it can lead to rapid death.
So injecting stem cells directly into the blood is unscientific and extremely dangerous.
Douglas et al. pointed out that the media can also play an important role in correctly promoting MSCs.
When you write about clinical institutions selling “mesenchymal stem cell therapy” and other so-called stem cell therapies, you should tell your readers that scientists still debate whether these cells really are stem cells.
Journalists should also make it clear that, in most cases, rigorous preclinical studies of these cells are limited or non-existent.
At the same time, organizations such as ISSCR, ISCT, and the National Stem Cell Association should ensure that guidelines, educational videos, and other communication tools designed for people receiving “adult stem cell therapy” are updated to reflect the end of MSCs as a viable concept.
Douglas et al. finally stressed that regardless of the ultimate identity and biological activity of cells previously named MSCs, misleading nomenclature and confusion concepts should be abandoned and the scientific principles guiding their clinical development and use must be consistent with other new therapies.